Atreca, Inc. (BCEL)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.6900 |
| Open | 1.7300 |
| Bid | 1.8000 x 1100 |
| Ask | 1.9000 x 900 |
| Day's Range | 1.6600 - 1.8600 |
| 52 Week Range | 1.5600 - 10.7300 |
| Volume | |
| Avg. Volume | 1,782,787 |
| Market Cap | 68.357M |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7900 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.63 |
- GlobeNewswire
Atreca to Present at Upcoming Investor Conferences
SAN CARLOS, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming investor conferences: H.C. Wainwright Global Investment ConferenceMay 23-26, 2022Presentation: 8:30 am EDT, May 25, 2022 Cowen’s 3rd Annual Oncology IO Next Sum
- GlobeNewswire
Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments
SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the first quarter ended March 31, 2022 and provided an overview of recent developments. "Atreca has had an exciting start to 2022, with multiple key clinical and preclinical milestones
- GlobeNewswire
Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101”
SAN CARLOS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the peer-reviewed publication of preclinical data demonstrating how its lead product candidate, ATRC-101, activates the immune system and drives tumor destruction in a Proceedings of the National Academy of
